ADJUPANRIX Trademark

Trademark Overview


On Friday, August 25, 2023, a trademark application was filed for ADJUPANRIX with the United States Patent and Trademark Office. The USPTO has given the ADJUPANRIX trademark a serial number of 98151423. The federal status of this trademark filing is REGISTERED as of Tuesday, June 25, 2024. This trademark is owned by GlaxoSmithKline Biologicals SA. The ADJUPANRIX trademark is filed in the Pharmaceutical Products category with the following description:

Vaccines
adjupanrix

General Information


Serial Number98151423
Word MarkADJUPANRIX
Filing DateFriday, August 25, 2023
Status700 - REGISTERED
Status DateTuesday, June 25, 2024
Registration Number7429357
Registration DateTuesday, June 25, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 9, 2024

Trademark Statements


Goods and ServicesVaccines

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, September 20, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGlaxoSmithKline Biologicals SA
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressRixensart B-1330
BE

Party NameGlaxoSmithKline Biologicals SA
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressRixensart B-1330
BE

Party NameGlaxoSmithKline Biologicals SA
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressRixensart B-1330
BE

Trademark Events


Event DateEvent Description
Tuesday, August 29, 2023NEW APPLICATION ENTERED
Wednesday, January 31, 2024ASSIGNED TO EXAMINER
Wednesday, January 31, 2024NON-FINAL ACTION WRITTEN
Wednesday, September 20, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, January 31, 2024NON-FINAL ACTION E-MAILED
Wednesday, January 31, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, March 1, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, March 1, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, March 1, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, March 20, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 9, 2024PUBLISHED FOR OPPOSITION
Tuesday, April 9, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 25, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, June 25, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Monday, March 4, 2024APPROVED FOR PUB - PRINCIPAL REGISTER

Related Keywords


adjupanrix vaccines